Aminomethylpyrimidines as novel DPP-IV inhibitors: A 105-fold activity increase by optimization of aromatic substituents
- 22 March 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (6) , 1491-1493
- https://doi.org/10.1016/j.bmcl.2004.01.019
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetesExpert Opinion on Therapeutic Patents, 2003
- Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs, 2003
- Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and β-Cell Glucose Responsiveness in VDF (fa/fa) Zucker RatsDiabetes, 2002
- Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine IntestineEndocrinology, 1999
- Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker ratsDiabetologia, 1999
- Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidideDiabetes, 1998
- Glucagon-like peptidesDiabetes, 1998
- Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IVEndocrinology, 1995
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993
- Reactions with α-substituted cinnamonitrilesTetrahedron, 1983